Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. (2nd January 2017)

• Record Type: Journal Article
• Authors: Kelley, Michael J.; Jha, Gautam; Shoemaker, Debra; Herndon, James E.; Gu, Lin; Barry, William T.; Crawford, Jeffrey; Ready, Neal
• Is Part Of: Cancer investigation. Volume 35:Number 1(2017)
• Page Start: 32
• Page End: 35
• Publication Date: 2017-01-02
• Subjects: Non-small cell lung cancer -- Src -- gene expression; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2016.1253710
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.